CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

被引：13

作者：

Le, Xiuning

Garassino, Marina Chiara

Cornelissen, Robin

Socinski, Mark A.

Tchekmedyian, Nishan

Molina, Julian R.

Baik, Christina S.

Leu, Sharon

Dreiling, Lyndah

Lebel, Francois M.

Clarke, Jeffrey Melson

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] IRCCS, Natl Canc Inst, Dept Med Oncol, Milan, Italy

[3] Erasmus MC, Rotterdam, Netherlands

[4] Advent Hlth Hematol & Oncol, Orlando, FL USA

[5] Pacif Shores Med Grp, Huntington Beach, CA USA

[6] Mayo Clin, Rochester, MN USA

[7] Seattle Canc Care Alliance, Seattle, WA USA

[8] Spectrum Pharmaceut, Irvine, CA USA

[9] Duke Univ, Med Ctr, Durham, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9093

引用

页数：2

共 50 条

[21] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity [J].

Elamin, Yasir Y. ;

Robichaux, Jacqulyne P. ;

Carter, Brett W. ;

Altan, Mehmet ;

Tran, Hai ;

Gibbons, Don L. ;

Heeke, Simon ;

Fossella, Frank, V ;

Lam, Vincent K. ;

Le, Xiuning ;

Negrao, Marcelo, V ;

Nilsson, Monique B. ;

Patel, Anisha ;

Vijayan, R. S. K. ;

Cross, Jason B. ;

Zhang, Jianjun ;

Byers, Lauren A. ;

Lu, Charles ;

Cascone, Tina ;

Feng, Lei ;

Luthra, Rajyalakshmi ;

San Lucas, Francis A. ;

Mantha, Geeta ;

Routbort, Mark ;

Blumenschein, George, Jr. ;

Tsao, Anne S. ;

Heymach, John, V .

CANCER CELL, 2022, 40 (07) :754-+

[22] Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. [J].

Yang, James Chih-Hsin ;

Wang, Mengzhao ;

Mitchell, Paul ;

Fang, Jian ;

Nian, Weiqi ;

Chiu, Chao-Hua ;

Zhou, Jianying ;

Zhao, Yanqiu ;

Su, Wu-Chou ;

Camidge, D. Ross ;

Yang, Tsung-Ying ;

Zhu, Viola Weijia ;

Millward, Michael ;

Fan, Yun ;

Huang, Wen Tsung ;

Cheng, Ying ;

Jiang, Liyan ;

Zheng, Li ;

Ye, Xiuhui ;

Janne, Pasi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[23] Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). [J].

Piotrowska, Zofia ;

Yu, Helena Alexandra ;

Yang, James Chih-Hsin ;

Koczywas, Marianna ;

Smit, Egbert F. ;

Tan, Daniel Shao-Weng ;

Lee, Victor Ho-Fun ;

Soo, Ross A. ;

Wrangle, John M. ;

Spira, Alexander I. ;

Velcheti, Vamsidhar ;

Socinski, Mark A. ;

Page, Asher ;

Witter, David ;

Zawel, Leigh ;

Wigginton, Jon M. ;

Clancy, Myles Steven ;

Nguyen, Danny .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[24] Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations [J].

Girard, N. ;

Bazhenova, L. ;

Minchom, A. ;

Ou, S. ;

Gadgeel, S. ;

Trigo, J. ;

Viteri, S. ;

Li, G. ;

Mahadevia, P. ;

Londhe, A. ;

Backenroth, D. ;

Li, T. ;

Bauml, J. M. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S145-S146

[25] Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations [J].

Ou, Sai-Hong Ignatius ;

Lin, Huamao M. ;

Hong, Jin-Liern ;

Yin, Yu ;

Jin, Shu ;

Lin, Jianchang ;

Mehta, Minal ;

Nguyen, Danny ;

Neal, Joel W. .

JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10)

[26] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment [J].

Yang, J. C. -H. ;

Wang, M. ;

Mitchell, P. ;

Fang, J. ;

Nian, W. ;

Chiu, C-H. ;

Zhou, J. ;

Zhao, Y. ;

Su, W. -C. ;

Camidge, R. ;

Yang, T. -Y. ;

Zhu, V. ;

Millward, M. ;

Fan, Y. ;

Huang, W. -T. ;

Cheng, Y. ;

Jiang, L. ;

Brungs, D. ;

Bazhenova, L. B. ;

Lee, C. K. ;

Gao, B. ;

Zheng, L. ;

Janne, P. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S410-S411

[27] EGFR EXON 20 INSERTION MUTATIONS IN NSCLC: FREQUENCY AND TREATMENT OUTCOMES WITH EGFR DIRECTED TKIS [J].

Ovcaricek, T. ;

Unk, M. ;

Kern, I. ;

Cufer, T. .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) :S64-S64

[28] A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC [J].

Choi, D. ;

Jung, H. A. ;

Park, S. ;

Sun, J-M. ;

Ahn, J. S. ;

Ahn, M-J. ;

Lee, S-H. .

ANNALS OF ONCOLOGY, 2023, 34 :S1696-S1696

[29] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations [J].

Bazhenova, Lyudmila ;

Minchom, Anna ;

Viteri, Santiago ;

Bauml, Joshua M. ;

Ou, Sai-Hong Ignatius ;

Gadgeel, Shirish M. ;

Manuel Trigo, Jose ;

Backenroth, Daniel ;

Li, Tracy ;

Londhe, Anil ;

Mahadevia, Parthiv ;

Girard, Nicolas .

LUNG CANCER, 2021, 162 :154-161

[30] Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies [J].

Le, X. ;

Prelaj, A. ;

Baik, C. ;

Tchekmedyian, N. ;

Leu, S. ;

Bhat, G. ;

Heymach, J. V. ;

Cornelissen, R. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S147-S148

← 1 2 3 4 5 →